Compare LII & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LII | SNN |
|---|---|---|
| Founded | 1895 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 12.3B |
| IPO Year | 1999 | 2002 |
| Metric | LII | SNN |
|---|---|---|
| Price | $404.61 | $29.09 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 2 |
| Target Price | ★ $566.58 | $36.25 |
| AVG Volume (30 Days) | 592.6K | ★ 1.4M |
| Earning Date | 04-29-2026 | 03-16-2026 |
| Dividend Yield | 1.00% | ★ 2.48% |
| EPS Growth | ★ 1.11 | N/A |
| EPS | ★ 3.35 | N/A |
| Revenue | ★ $5,195,300,000.00 | N/A |
| Revenue This Year | $6.85 | $8.58 |
| Revenue Next Year | $5.76 | $5.60 |
| P/E Ratio | $125.18 | ★ $64.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $407.94 | $28.56 |
| 52 Week High | $597.81 | $38.79 |
| Indicator | LII | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 40.03 |
| Support Level | N/A | N/A |
| Resistance Level | $544.42 | $31.18 |
| Average True Range (ATR) | 12.46 | 0.47 |
| MACD | -0.30 | -0.16 |
| Stochastic Oscillator | 1.08 | 1.16 |
Lennox manufactures and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounts for 67% of sales and commercial HVAC (building climate solutions) accounts for the remaining 33% of sales. Lennox's commercial exposure is what its peers refer to as residential and light commercial, and lacks the scale and complexity of what is referred to as an applied solution. The company goes to market with multiple brands, but Lennox is its flagship HVAC brand.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.